Evidence map›Paper›PMID 39840152›Full record

ArticleCureus2024

Assessment of Non-alcoholic Fatty Liver Disease and Level of Risk of Fibrosis in Diabetic and Non-diabetic Individuals.

Miah Wahiduzzaman, Noor-E- Ferdous, K M Mozibul Haque, A K M Shamsul Kabir, Md Adib Siddiki, Md Tanim Hossain, Qazi Ashrafur Rahman, Al Istiak Ur Rahman, A H M Golam Kibria

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Miah WahiduzzamanMedicine, Holy Family Red Crescent Medical College and Hospital, Dhaka, BGD.
Noor-E- FerdousGynecological Oncology, Bangabandhu Sheikh Mujib Medical University, Dhaka, BGD.
K M Mozibul HaqueAnesthesiology and ICU, Holy Family Red Crescent Medical College and Hospital, Dhaka, BGD.
A K M Shamsul KabirMedicine, Holy Family Red Crescent Medical College and Hospital, Dhaka, BGD.
Md Adib SiddikiMedicine, Holy Family Red Crescent Medical College and Hospital, Dhaka, BGD.
Md Tanim HossainMedicine, Holy Family Red Crescent Medical College and Hospital, Dhaka, BGD.
Qazi Ashrafur RahmanMarketing Pharma-Human, Renata Public Limited Company, Dhaka, BGD.
Al Istiak Ur RahmanMarketing Pharma-Human, Renata Public Limited Company, Dhaka, BGD.
A H M Golam KibriaEpidemiology and Biostatistics, Center for Medical Research and Development (CMRD), Dhaka, BGD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aim Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is more common in people with type-2 diabetes mellitus (T2DM) than in people without diabetes mellitus (non-DM). This disease can lead to cirrhosis or hepatic cancer. There is limited data on NAFLD prevalence and the level of risk of fibrosis in Bangladeshi individuals. This study aimed to assess NAFLD prevalence and compare the proportion of NAFLD and the level of risk of fibrosis between T2DM and non-DM Bangladeshi individuals. Methods A cross-sectional analytical study was conducted for six months in 2024 in the outpatient section of the Department of Medicine at Holy Family Red Crescent Medical College, Dhaka, Bangladesh. Among the patients seeking outpatient care, a total of 179 male and non-pregnant female participants aged 18 years and older were selected using a purposive sampling technique. Individuals with a history of alcohol use, diagnosed cases of chronic liver diseases, prior use of hepatotoxic drugs, and primary biliary cholangitis were excluded from the study. Detailed demographic characteristics, comorbidities, family history of diabetes and liver disease, physical measurements, and biochemical tests were done. Ultrasonography (USG) of the hepatobiliary system was employed to ascertain the existence of NAFLD. The presence or absence of T2DM was evaluated through prior medical documents, corroborated by laboratory analyses of random blood glucose (RBS) and glycosylated hemoglobin (HbA1c) levels. The Fibrosis-4 (FIB-4) index score was utilized to evaluate the risk of liver fibrosis. Results The mean age of the participants was 49.11±12.25 years and 107 (59.8%) of participants were female. Almost two-thirds of the participants were suffering from T2DM. About 17 (9.5%) of the study participants were suffering from NAFLD, which was much higher among T2DM (15 (12.5%)) than non-DM individuals (two (3.3%)). T2DM and family history of liver disease were found to significantly increase the risk of suffering from NAFLD by 5.247 times (95% CI: 1.081-25.468) and 4.202 times (95% CI: 1.249-14.135), respectively. About one (6.7%) of T2DM individuals with NAFLD were at high risk for fibrosis. Conclusion Almost one in 10 people had NAFLD, and it was way more common among those with T2DM, who also exhibit a higher risk of hepatic fibrosis. Moreover, T2DM and a family history of liver disease can independently increase the risk of NAFLD.

Indexed as

family history of liver diseasefibrosis-4 indexmetabolic dysfunction-associated steatotic liver disease (masld)non-alcoholic fatty liver disease (nafld)non-diabetic individualstype 2 diabetes mellitus (t2dm)ultrasonography

Identifiers

PMID39840152
PMCPMC11747980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.